Market Overview

Sanofi Ventures Leads $17 Million Financing of Click Therapeutics

Share:

Click
Therapeutics, Inc.
("Click"), a leader in Digital Therapeutics™
solutions as prescription medical treatments, announces a $17 million
financing round led by Sanofi Ventures. Click will use this financing to
continue advancing its proprietary platform and pipeline of prescription
digital therapeutics to treat a wide range of diseases. Recent notes
were converted to equity as part of the financing.

"We've evaluated many companies in this space, and we believe Click
Therapeutics' mobile patient engagement platform positions the company
to be a leader in the field of prescription digital therapeutics," said
Bernard Davitian, SVP and Managing Director of Sanofi Ventures, who has
joined Click's Board in conjunction with the financing. "Click's
platform enables the company to target multiple indications efficiently
and effectively, and we have invested with the intent of partnering
across a variety of therapeutic areas. Sanofi Ventures is excited to
join Click on this journey of building a new pillar of medicine."

In addition to Clickotine®, Click's commercial product for smoking
cessation, the company is developing prescription digital therapeutics
for the treatment of depression (CT-152), insomnia (CT-141), acute
coronary syndrome (CT-111), and chronic pain (CT-130). Click will seek
FDA clearance for these programs as class II medical devices with
disease-specific treatment claims, to be prescribed by physicians and
reimbursed by payers.

"The Click Therapeutics team is proud to partner with Sanofi Ventures to
advance our pipeline and expand our product portfolio of prescription
medical treatments," remarked David Benshoof Klein, Co-founder and CEO
of Click. "As we announced last summer, in 2017 we expanded our
collaboration with Magellan Health, Inc. to pursue regulatory clearance
from the FDA for indication-specific prescription digital therapies,
leveraging the industry-leading suite of intellectual property and data
from Magellan's existing software as well as their vast coverage and
reimbursement leadership. The addition of Sanofi as a strategic
investor, and the closing of this financing, represent major steps
forward for Click and for the field of software as prescription medical
treatments. By connecting patients with cognitive and neurobehavioral
interventions, our platform will bring clinically-validated digital
therapeutic solutions into mainstream healthcare."

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi
Ventures invests in early-stage biotech and digital health companies
with innovative ideas and transformative new products and technologies
of strategic interest to Sanofi. Among these areas are rare diseases,
vaccines, potential cures in other core areas of Sanofi's business
footprint, and digital health solutions. For more information, visit www.sanofiventures.com.

About Magellan Health

Magellan
Health, Inc.
, a Fortune
500 company
, is a leader in managing
the fastest growing, most complex areas of health, including special
populations, complete pharmacy benefits and other specialty areas of
healthcare. Magellan supports innovative ways of accessing better health
through technology, while remaining focused on the critical personal
relationships that are necessary to achieve a healthy, vibrant life.
Magellan's customers include health plans and other managed care
organizations, employers, labor unions, various military and
governmental agencies and third-party administrators. For more
information, visit MagellanHealth.com.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as
prescription medical treatments for people with unmet medical needs.
Through cognitive and neurobehavioral mechanisms, Click's Digital
Therapeutics™ enable change within individuals, and are designed to be
used independently or in conjunction with biomedical treatments. The
Clickometrics® adaptive data science platform continuously personalizes
user experience to optimize engagement and outcomes. Following a
groundbreaking clinical trial, Click's industry-leading smoking
cessation program is available nationwide through a wide variety of
payers, providers, and employers. Click's lead prescription program is
entering into a multi-center, randomized, controlled, parallel-group,
phase III FDA registration trial for the treatment of Major Depressive
Disorder in adults. For more information, visit ClickTherapeutics.com.

View Comments and Join the Discussion!